**Specifications Table**TableSubject areaBiochemistry, Molecular biologyMore specific subject areaMolecular endocrinology, Gynecological endocrinologyType of dataTablesHow data was acquiredClinical and histopathological data was obtained from the patients' medical and histopathological records, respectively.The gene expression data obtained by quantitative real-time PCR was statistically analyzed.Data formatAnalyzedExperimental factorsExperimental featuresRatios for expression of 38 genes in samples of endometrial cancer *versus* adjacent control endometrium were calculated and this data was statistically analyzed.Data source locationLjubljana, SloveniaData accessibilityThe statistically analyzed data is available within this article and the raw expression data may be provided upon request.

**Value of the data**•Data on correlations between the expression ratios of these 38 genes and demographic characteristics may be helpful for explanation of different etiological factors identified in epidemiological studies.•Data on changes in the expression ratios of these 38 genes according to histopathological and clinical data may lay foundation for further investigations of individual players of the individual pathophysiological processes.

1. Data {#s0005}
=======

We provide data on demographic, histopathological and clinical characteristic of 51 endometrial cancer patients treated at the University Medical Centre Ljubljana, at the Division of Gynaecology and Obstetrics. Demographic (age, body mass, BMI, menopausal status, parity), histopathological and clinical data (histological type and grade of tumor, depth of myometrial invasion, presence of lymphovascular invasion, FIGO stage) ([Table 1](#t0005){ref-type="table"}) together with data on statistical analysis of gene expression ratios ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}) are included. The study was approved by the National Medical Ethics Committee of the Republic of Slovenia.Table 1Demographic, histopathological and clinical characteristics of the endometrial cancer patients.Table 1**SampleAgeBody massBMIAge at last menstruationParityFIGO stageHistological grade (low/high)Myometrial invasion (yes/no)Myometrial invasion \>1/2 (yes/no)Lymphovascular invasion (yes/no)1**395921.7premenopausal1IBhighyesyesyes**2**83NANA504IBhighyesyesno**3**4113046.1premenopausal1IAlowyesnono**4**537928.3501IAlownonono**5**606825.0561IBlowyesyesyes**6**646326.2501IVlowyesnoNA**7**739534.1451IBlowyesyesno**8**698331.6591IAlowyesnono**9**798432.8492IBlowyesyesno**10**747528.6501IAlowyesnono**11**768332.4561IAlowyesnono**12**537027.3premenopausal3IAlownonono**13**369233.8premenopausal2IAlownonono**14**455520.0premenopausal1IAlownonono**15**696825.353IBlowyesyesyes**16**546523.0premenopausal0IAhighNAnono**17**7210035.9451IAlowNAnono**18**545119.9premenopausal2IAlownonono**19**698230.1650IBhighyesyesyes**20**7785NA501IBhighyesyesno**21**5710438.2562IAlownono**22**618830.8502IAlownonono**23**7869NA502IAlowyesnoyes**24**637531.6553IAlowyesnoyes**25**718029.4592IAhighyesnono**26**818228.4512IAlowNAnono**27**736524.8480IBhighyesyesyes**28**508832.3premenopausal1IIIAlowyesnono**29**275720.0premenopausal0IAhighyesnono**30**596019.4402IBhighyesyesyes**31**7011947.7501IAlowyesnono**32**7310034.6532IAlowyesnono**33**757330.4553IAlowyesyesyes**34**7513048.9503IAlowyesnoyes**35**5086NANA1IAhighyesnoyes**36**7110041.1544IAlowyesnono**37**756024.0501IIIC1highyesyesyes**38**559538.1544IAlownonono**39**4311044.6premenopausal2IAlownonono**40**688734.9532IAlowyesnono**41**839033.1552IAlownonono**42**5910237.5521IAlownonono**43**669334.6571IAlowyesnono**44**666725.5522IAlowyesnono**45**805928.1501IBhighyesyesyes**46**726727.5503IAlowyesnono**47**447929.0premenopausal2IAlownonono**48**456020.8premenopausal2IIlowyesnono**49**728029.4582IAlowyesnono**50**5597NA582IBhighyesyesNA**51**4894NApremenopausal2IAhighyesnono[^3]Table 2Correlations between expression of genes involved in estrogen biosynthesis and action and demographic characteristics of endometrial cancer patients.Table 2**GeneAgeBody massBMIAge at menopauseParityRho*****p*****Adj.*p******N*****Rho*****P*****Adj.*****N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj.*p******N****AKR1C3***-0.1590.4591.00024-0.0290.8950.89523-0.0120.9601.000210.2310.3560.94918**-0.473**[\*](#tbl2fnStar){ref-type="table-fn"}**0.0220.35223*****CYP19A1***-0.1100.6100.97624-0.1080.6230.90623-0.0100.9641.00021-0.0320.8991.000180.1290.5571.00023***HSD17B2*****0.3550.0170.27245**0.1730.2621.000440.2090.1901.00041**-0.360**[\*](#tbl2fnStar){ref-type="table-fn"}**0.0430.68832**0.2450.1090.87244***HSD17B1***0.0000.9980.99829-0.1160.5581.00028-0.1790.3811.000260.1070.6520.869200.0590.7671.00028***HSD17B4***-0.0970.6540.87224-0.0560.8000.853230.0860.7121.000210.1380.5850.851180.0790.7191.00023***HSD17B8***0.0180.9341.00024-0.1220.5791.00023-0.2030.3781.000210.0280.9131.00018-0.3100.1500.80023***HSD17B14***-0.1500.4951.000230.1920.3931.000220.2380.3131.000200.1730.5070.811170.2570.2490.99622***HSD17B12***0.1150.5931.000240.0900.6830.91123-0.0010.9960.99621-0.2780.2641.00018-0.0830.7081.00023***SULT1E1***0.1920.2551.000370.1270.4611.000360.1220.4991.00033-0.2130.2850.912270.0160.9250.98736***STS***0.1090.5731.000290.0630.7510.858280.0620.7631.000260.1710.4720.83920-0.0120.9520.95228***SULT2A1***-0.1010.5531.00037-0.0880.6100.97636-0.0770.6691.000330.0190.9260.98827-0.1300.4511.00036***SULT2B1***-0.0120.9461.000370.2010.2391.000360.1980.2701.000330.0160.9370.937270.0930.5881.00036***ESR1***-0.0310.8451.00042-0.0620.7000.86241-0.0900.5921.00038**-0.3640.0480.38430**0.0200.8991.00041***ESR2*****-0.3550.0210.16842**-0.0870.5891.00041-0.0700.6781.000380.1560.4110.822300.0980.5411.00041***GPER2***0.0880.6430.93530-0.3610.0540.86429-0.2540.2011.000270.2010.3830.875210.0850.6601.00029***GPER34***0.1160.5401.00030-0.1560.4201.00029-0.0490.8100.997270.2900.2021.000210.0480.8060.99229[^4][^5]Table 3Correlations between expression of genes involved in estrogen oxidative metabolism and demographic characteristics of endometrial cancer patients.Table 3**GeneAgeBody massBMIAge at menopauseParityRho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N****SULT1E1***0.1920.2550.850370.1270.4610.922360.1220.4990.99833-0.2130.2850.950270.0160.9251.00036***CYP1A1***0.2870.0850.85037-0.0290.8660.96236-0.0450.8031.000330.0030.9890.98927-0.0860.6190.88436***CYP1B1***0.0210.9000.90037-0.0900.6020.86036-0.0270.8810.881330.0400.8441.00027-0.0330.8471.00036***CYP1A2***0.2380.1570.78537-0.1440.4021.00036-0.1190.5080.847330.0480.8111.000270.1730.3121.00036***CYP3A5***0.0280.8690.96637-0.1300.4501.00036-0.1550.3881.000330.1020.6121.00027-0.1290.4530.90636***CYP3A7***-0.1570.3530.88337-0.2520.1391.00036-0.2180.2221.00033-0.0080.9701.00027-0.2310.1750.87536***COMT***-0.1350.4260.852370.0050.9770.97736-0.0290.8740.971330.2090.2950.73827-0.2880.0890.89036***UGT2B7***0.1170.4900.817370.0470.7860.983360.0320.8591.000330.3180.1060.530270.0080.9630.96336***SULT1A1***-0.0510.7650.95637-0.2180.2011.00036-0.2050.2531.000330.0590.7711.00027-0.1670.3300.82536***GSTP1***-0.0710.6840.977350.1090.5380.897340.1400.4531.00031**0.511**^\*\*^**0.0080.08026**0.1180.5070.84534[^6]Table 4Correlations between expression of genes involved in progesterone biosynthesis and action and demographic characteristics of endometrial cancer patients.Table 4**GeneAgeBody massBMIAge at menopauseParityRho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******n*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N****PGR***-0.0890.5630.845450.0810.6031.000440.0160.9200.92041-0.0760.6800.874320.1820.2380.53644***PAQR7*****-0.455^\*^0.0020.01845**-0.0190.9030.90344-0.1130.4821.000410.2770.1250.563320.2200.1500.67544***PAQR5***-0.0340.8260.82645-0.2260.1400.63044-0.1720.2821.000410.0490.7910.89032-0.1240.4220.63344***PAQR8***-0.1370.3820.86043-0.0720.6531.00042-0.0760.6461.00039**-0.436^\*^0.0140.12631**-0.1040.5140.66142***PRB***0.0700.6490.834450.0720.6401.000440.0660.6831.00041-0.1280.4850.728320.2480.1050.94544***STAR***-0.1940.2020.60645**0.358^\*^0.0170.153440.374^\*^0.0160.14441**0.2260.2130.479320.2070.1780.53444***HSD3B1***0.1150.4910.884380.0210.9021.00037-0.0480.7871.000340.0080.9670.967290.0550.7480.84237***HSD3B2***-0.0650.7000.788370.0750.6650.998360.0440.8090.91033-0.1940.3330.59927-0.0140.9350.93536***CYP11A1***-0.2430.1080.48645-0.0500.7470.96044-0.1390.3871.000410.2510.1660.498320.1550.3150.56744[^7]Table 5Correlations between expression of genes involved in progesterone metabolism and demographic characteristics of endometrial cancer patients.Table 5**GeneAgeBody massBMIAge at menopauseParityRho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj.*p******N*****Rho*****p*****Adj.*p******N****SRD5A1***-0.2120.2700.54029**-0.531^\*\*^0.0040.02428-0.533^\*\*^0.0050.03026**-0.2180.3560.53420**-0.382^\*^0.0450.13528*****SRD5A2*****0.439^\*^0.0170.10229**-0.1890.3360.67228-0.0850.6781.00026-0.0370.8760.876200.2410.2170.32628***AKR1C1***-0.0280.8540.854450.0100.9501.00044-0.0480.7640.917410.2980.0970.29132-0.0880.5680.56844***AKR1C2***0.0360.8170.980450.0030.9860.98644-0.0800.6201.000410.2970.0990.19832-0.1560.3130.37644***AKR1C3***-0.1590.4590.68924-0.0290.8951.00023-0.0120.9600.960210.2310.3560.42718**-0.473^\*^0.0220.13223*****HSD17B2***^\*^**0.0170.05145**0.1730.2620.786440.2090.1900.57041-^\*^**0.0430.25832**0.2450.1090.21844[^8]Table 6Correlations between expression of genes involved in PGF2α biosynthesis and retinoic acid metabolism and demographic characteristics of endometrial cancer patients.Table 6**GeneAgeBody massBMIAge at menopauseParityRho*****P*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N*****Rho*****p*****Adj. *p******N****AKR1B1***-0.2780.0640.19245**-0.357^\*^0.0170.02644-0.332^\*^0.0340.05141**-0.2270.2110.63332-0.1060.4950.49544***AKR1B10***0.0360.8150.81545**0.481^\*\*^0.0010.003440.516^\*\*^0.0010.00341**0.0460.8040.804320.2490.1030.15544***AKR1C3***-0.1590.4590.68924-0.0290.8950.89523-0.0120.9600.960210.2310.3560.53418**-0.473**[⁎](#tbl6fnStar){ref-type="table-fn"}**0.0220.06623**[^9][^10]Table 7Changes in expression of genes involved in estrogen biosynthesis and action according to histopathological and clinical characteristics of endometrial cancer patients.Table 7:**Histological grade (high grade*****vs.*****low grade)FIGO stage (IA*****vs.*****IB-IV)Menopausal statusMyometrial invasion (yes/no)Myometrial invasion \>1/2 (yes/no)Lymphovascular invasion invasion (yes/no)Adj.*p******p****p*****Adj.*p******p****p****p*****Adj.*p******AKR1C3***0.8250.8800.3060.4240.7540.5550.1000.8040.99***CYP19A1***0.7120.8760.219**0.0110.176**0.8830.0680.6800.989***HSD17B2*****0.0100.160**0.251**0.0280.224**0.9390.1990.9610.961***HSD17B1*****0.0190.101**0.2880.7410.8470.0600.6900.0750.600***HSD17B4*****0.0100.080**0.785110.5070.5840.3640.582***HSD17B8***0.5070.6760.8910.3170.8450.3380.2730.1170.624***HSD17B14***0.2760.5520.8850.6740.8990.5630.4300.3590.718***HSD17B12***0.2100.4800.9460.4630.7410.6060.2730.2150.491***SULT1E1***0.0720.2300.0600.3210.7340.7610.3130.1770.566***STS***0.4570.6650.9150.7060.8690.5800.0840.9121***SULT2A1***0.8050.9200.5910.7580.8090.1830.922**0.0040.064*****SULT2B1*****0.0440.176**0.7370.1320.5280.4930.4950.3610.642***ESR1***0.9010.9010.8310.3300.660.1820.4540.2100.560***ESR2***0.3330.5920.7380.1130.6030.7390.2550.1500.600***GPER2***0.4460.7140.7990.4830.7030.9190.2880.9150.976***GPER34***0.1860.49610.2680.8580.4160.5070.710.947[^11]Table 8Changes in expression of genes involved in estrogen oxidative metabolism according to histopathological and clinical characteristics of endometrial cancer patients.Table 8**Histological grade (high grade*****vs.*****low grade)FIGO stage (IA*****vs.*****IB-IV)Menopausal statusMyometrial invasion (yes/no)Myometrial invasion \>1/2 (yes/no)Lymphovascular invasion invasion (yes/no)*****P****p****p****p****p****p****SULT1E1***0.0720.0600.3210.7610.3130.177***CYP1A1***0.5480.7370.6820.0870.1260.290***CYP1B1***0.5250.5680.9730.0680.1430.290***CYP1A2***0.6980.5910.4120.7320.3130.511***CYP3A5***0.5720.4020.1320.5940.2550.688***CYP3A7***0.8880.4810.9180.5940.6260.798***COMT***0.6720.8400.9450.4240.0970.535***UGT2B7***0.9160.1490.1710.5680.9220.535***SULT1A1***0.0970.9200.2060.3810.9220.342***GSTP1***0.7200.0940.8060.5120.4760.147[^12]Table 9Changes in expression of genes involved in progesterone biosynthesis and action according to histopathological and clinical characteristics of endometrial cancer patients.Table 9**Histological grade (high grade*****vs.*****low grade)FIGO stage (IA*****vs.*****IB-IV)Menopausal statusMyometrial invasion (yes/no)Myometrial invasion \>1/2 (yes/no)Lymphovascular invasion invasion (yes/no)*****p*****Adj.*p******p****p*****Adj.*p******p****p*****Adj.*p******p****PGR***0.0700.2100.3370.70710.9390.2680.4020.710***PAQR7***0.1910.4300.1650.0540.2430.417**0.0100.09**0.859***PAQR5***0.88910.7290.90010.6130.1800.3240.102***PAQR8***0.4790.7190.7180.1760.5280.8590.0540.1220.363***PRB*****0.0260.117**0.5390.80210.5300.5210.5860.616***STAR*****0.0010.009**0.0780.9000.90.702**0.0410.123**0.409***HSD3B1***0.9040.9040.1180.69310.2520.6260.6260.224***HSD3B2***0.4370.7870.2020.3930.8840.7040.4540.5840.742***CYP11A1***0.7380.9490.157**0.0280.252**0.657**0.0360.162**0.528[^13]Table 10Changes in expression of genes involved in progesterone metabolism according to histopathological and clinical characteristics of endometrial cancer patients.Table 10**Histological grade (high grade*****vs.*****low grade)FIGO stage (IA*****vs.*****IB-IV)Menopausal statusMyometrial invasion (yes/no)Myometrial invasion \>1/2 (yes/no)Lymphovascular invasion invasion (yes/no)*****p*****Adj.*p******p****p*****Adj.*p******p****p*****Adj.*p******p****SRD5A1***0.2220.4440.1370.1090.2180.4720.5070.5070.541***SRD5A2***0.0560.1680.367**0.0480.144**0.3190.3520.4220.739***AKR1C1***0.4860.7290.1220.9200.9200.842**0.0200.120**0.987***AKR1C2***0.5220.6260.0880.5310.6370.842**0.0230.069**0.662***AKR1C3***0.8250.8250.3060.4240.6360.5550.1000.2000.804***HSD17B2*****0.0100.060**0.251**0.0280.168**0.9390.1990.2990.961[^14]Table 11Changes in expression of genes involved in PGF2α biosynthesis and retinoic acid metabolism according to histopathological and clinical characteristics of endometrial cancer patients.Table 11**Histological grade (high grade*****vs.*****low grade)FIGO stage (IA*****vs.*****IB-IV)Menopausal statusMyometrial invasion (yes/no)Myometrial invasion \>1/2 (yes/no)Lymphovascular invasion invasion (yes/no)*****p*****Adj.*p******p****p*****Adj.*p******p****p****p*****Adj.*p******AKR1B1***0.0700.1050.729**0.0260.078**0.8420.5210.3730.56***AKR1B10*****0.0010.003**0.0550.0750.1130.0830.08**0.0370.111*****AKR1C3***0.8250.8250.3060.4240.4240.5550.10.8040.804[^15]

1.1. Demographic, histopathological and clinical data {#s0010}
-----------------------------------------------------

The demographic, histopathological and clinical characteristics are given in [Table 1](#t0005){ref-type="table"}. For the 51 patients, the mean age was 63.16 years (SD, 13.33 years; range, 26.72--83.58 years), the mean body weight was 81.24 kg (SD, 17.25 kg; range, 51--130 kg), and the mean BMI was 30.63 kg/m^2^ (SD, 6.95 kg/m^2^; range, 19.37--48.93 kg/m^2^). According to the WHO definitions, of the 46 patients with BMI data, 10 (21.7%) were within the normal range (BMI, 18.5--25.0 kg/m^2^), 12 (26.1%) were overweight (BMI, 25--30 kg/m^2^), and 24 (52.2%) were obese (BMI, \>30 kg/m^2^), with 15 (32.6%) as moderately obese (BMI, 30--35 kg/m^2^), 5 (10.9%) as severely obese (BMI, 35--40 kg/m^2^), and 4 (8.7%) as very severely obese (BMI, \>40 kg/m^2^).

Forty-six (92.0%) of the 50 patients with the relevant data had at least one full-term pregnancy, four (8.0%) had none. Information for menopausal status was also available for 50 patients, with 38 (76.0%) post-menopausal and 12 (24.0%) pre-menopausal. The minimum age at the last menstruation was 40 years, and the maximum was 65 years, with the mean of 52.34 years (SD, 4.54 years). The longest post-menopausal time before analysis was 33.6 years.

The Cancer Registry of the Republic of Slovenia was searched for the vital status of these 51 patients. The cut-off point was June 20, 2016, at which date 36 (70.6%) of these patients were still alive, and 15 (29.4%) were dead. The mean age at death was 75.36 years (SD, 9.30 years), with the minimum age at death of 57.05 years, and maximum age of 86.44 years. Eight patients (15.7%) died of cancer: four (7.8%) of uterine cancer, one of ovarian cancer, one of kidney cancer, one of malignant melanoma of the skin, and one of glioblastoma (2.0%, for each). Three patients (5.9%) died of chronic ischemic heart disease, one of atherosclerotic arteries of the extremities, one of benign meningeal neoplasm, and one of infection and inflammatory reaction due to an internal joint prosthesis (2.0%, for each). Morbid obesity with alveolar hypoventilation resulted in the death of one of the patients (2.0%).

The most common histologic type was endometrioid adenocarcinoma, as seen for 41 of the 51 patients (80.4%), of these, 29 (70.7%) had tumor grade 1 (G1), eight (19.5%) grade 2 (G2), and five (12.2%) grade 3 (G3). Five (9.80%) of the 51 patients had serous carcinoma, one (2.0%) had mucinous carcinoma, one (2.0%) had carcinosarcoma, and three (5.9%) had dedifferentiated carcinoma. At histologic examination, the tumor tissue was limited to the endometrium in 12 (23.5%) of the 51 patients, invasion into the myometrium (\<50% of myometrial thickness) was seen in 25 (49.0%), and deep tumor invasion (≥50% of myometrial thickness) was seen in 14 (27.5%). For one patient (2.0%), the tumor tissue had spread to the adjacent tissue to the right fallopian tube, while histological examination revealed pelvic lymph node metastases for one patient (2.0%). According to the International Federation of Gynecology and Obstetrics (FIGO) staging, 33 (66.0%) were classified as stage IA, 11 (22.0%) as stage IB, one (2.0%) as stage II, two (4.0%) as stage III, one as stage IIIA, one as stage IIIC1, and one as stage IV (2.0%, for each).

2. Experimental design, materials and methods {#s0015}
=============================================

2.1. Gene expression ratios in cancer *versus* adjacent control tissue {#s0020}
----------------------------------------------------------------------

We investigated expression of genes encoding enzymes of estrogen biosynthesis [@bib2] (Figure 1, [@bib1]), enzymes of estrogen metabolism [@bib3] (Figure 2, [@bib1]), enzymes of progesterone synthesis and metabolism [@bib4] (Figures 3 and 4, [@bib1]) and enzymes of PGF2α synthesis and metabolism of retinoic acid [@bib5] (Figure 5, [@bib1]). We also investigated expression of nuclear estrogen and progesterone receptors *ESR1*, *ESR2* [@bib2], [@bib6], *PGR*, *PRB* [@bib4]*,* and membrane bound estrogen and progesterone receptors *GPER*, *PAQR5*, *PAQR7* and *PAQR8* (manuscript in preparation) (Figures 2 and 3, [@bib1]). Our studies comprised from 22 to 47 patients. To provide information about up/down-regulation of these 38 genes in cancer *versus* adjacent control tissue we calculated ratios for gene expression in tumor/ adjacent control tissue and these data were statistically analyzed.

2.2. Statistical analysis {#s0025}
-------------------------

The correlations between the ratios for expression of 38 genes in tumor/ adjacent control tissue and demographic parameters were evaluated by calculating Spearman׳s correlation coefficient rho ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}). The statistical significant changes in the ratios for expression of 38 genes in tumor/ adjacent control tissue with regard to histopathological and clinical characteristics were tested using the Mann-Whitney test and the Wilcoxon W test, followed by Benjamini and Hochberg corrections for multiple testing [@bib7] ([Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}).

Transparency document. Supplementary material {#s0035}
=============================================
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[^1]: Current address: Department of Gastroenterology, General Hospital Celje, Celje, Slovenia.

[^2]: Current address: Department of Haematology, University Medical Centre Ljubljana, Ljubljana, Slovenia.

[^3]: NA, not available.

[^4]: Spearman׳s rho correlation coefficient (Rho) and 2-tailed significance (p) and adjusted significance (Adj. p) and N number of endometrial cancer cases are shown.

[^5]: Correlation is significant at the 0.05 level (2-tailed).

[^6]: Spearman׳s rho correlation coefficient (Rho) and 2-tailed significance (*p*) and adjusted significance (Adj. *p*) and N number of endometrial cancer cases are shown. \*\* Correlation is significant at the 0.001 level (2-tailed).

[^7]: Spearman׳s rho correlation coefficient (Rho) and 2-tailed significance (*p*) and adjusted significance (Adj. *p*) and N number of endometrial cancer cases are shown. \* Correlation is significant at the 0.05 level (2-tailed).

[^8]: Spearman׳s rho correlation coefficient (Rho) and 2-tailed significance (*p*) and adjusted significance (Adj. *p*) and *N* number of endometrial cancer cases are shown. \* Correlation is significant at the 0.05 level (2-tailed), \*\*Correlation is significant at the 0.001 level (2-tailed).

[^9]: Spearman׳s rho correlation coefficient (Rho) and 2-tailed significance (*p*) and adjusted significance (Adj. *p*) and *N* number of endometrial cancer cases are shown.

[^10]: Correlation is significant at the 0.05 level (2-tailed), ​\*\* Correlation is significant at the 0.001 level (2-tailed).

[^11]: Changes in gene expression ratios were tested using Mann-Whitney nonparametric tests for two-group comparisons, and Wilcoxon nonparametric W tests. Corrections for multiple testing were performed according to Benjamini and Hochberg [@bib7]. Asymptotic 2-tailed significance (*p*) and adjusted significance (Adj. *p*) are shown. Adj. *p* was calculated only in the groups where *p* \< 0.05.

[^12]: Changes in expression were tested using Mann-Whitney nonparametric tests for two-group comparisons, and Wilcoxon nonparametric W tests. Corrections for multiple testing were performed according to Benjamini and Hochberg [@bib7]. Asymptotic 2-tailed significance (*p*) is shown.

[^13]: Changes in expression were tested using Mann-Whitney nonparametric tests for two-group comparisons, and Wilcoxon nonparametric W tests. Corrections for multiple testing were performed according to Benjamini and Hochberg [@bib7]. Asymptotic 2-tailed significance (*p*) and adjusted significance (Adj. *p*) are shown. Adj. *p* was calculated only in the groups where *p* \< 0.05.

[^14]: Changes in expression were tested using Mann-Whitney nonparametric tests for two-group comparisons, and Wilcoxon nonparametric W tests. Corrections for multiple testing were performed according to Benjamini and Hochberg [@bib7]. Asymptotic 2-tailed significance *(p*) and adjusted significance (Adj. *p*) are shown. Adj. *p* was calculated only in the groups where *p* \< 0.05.

[^15]: Changes in expression were tested using Mann-Whitney nonparametric tests for two-group comparisons, and Wilcoxon nonparametric W tests. Corrections for multiple testing were performed according to Benjamini and Hochberg [@bib7]. Asymptotic 2-tailed significance (*p*) and adjusted significance (Adj. *p*) are shown. Adj. *p* was calculated only in the groups where *p* \< 0.05.
